Study: Lung squamous patients harboring druggable mutations have lower median overall survival

Oncotarget published “Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations” which reported that unlike lung adenocarcinoma patients, there is no FDA-approved targeted-therapy likely to benefit lung squamous cell carcinoma patients.